Past, Present, and a Glance into the Future of Multiple Myeloma Treatment

被引：10

作者：

Elbezanti, Weam Othman ^{[1
,2
]}

Challagundla, Kishore B. ^{[3
]}

Jonnalagadda, Subash C. ^{[4
]}

Budak-Alpdogan, Tulin ^{[2
]}

Pandey, Manoj K. ^{[1
]}

机构：

[1] Rowan Univ, Dept Biomed Sci, Cooper Med Sch, 401S Broadway, Camden, NJ 08103 USA

[2] MD Anderson Canc Ctr Cooper, Dept Hematol, Cooper Hlth Syst, Camden, NJ 08103 USA

[3] Univ Nebraska, Child Hlth Res Inst, Fred & Pamela Buffett Canc Ctr, Dept Biochem & Mol Biol,Med Ctr, Omaha, NE 68198 USA

[4] Rowan Univ, Dept Chem & Biochem, Glassboro, NJ 08028 USA

来源：

PHARMACEUTICALS | 2023年 / 16卷 / 03期

关键词：

multiple myeloma; B-cell malignancy; bone marrow microenvironment; drug resistance; proteasome inhibitors; immunotherapies; MEDIATED DRUG-RESISTANCE; NATURAL-KILLER-CELL; KAPPA-B ACTIVATION; RNA-POLYMERASE-II; BONE-MARROW; PROTEASOME INHIBITOR; OPEN-LABEL; THERAPEUTIC TARGET; POOR-PROGNOSIS; PHASE-III;

D O I：

10.3390/ph16030415

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Multiple myeloma (MM) is a challenging hematological cancer which typically grows in bone marrow. MM accounts for 10% of hematological malignancies and 1.8% of cancers. The recent treatment strategies have significantly improved progression-free survival for MM patients in the last decade; however, a relapse for most MM patients is inevitable. In this review we discuss current treatment, important pathways for proliferation, survival, immune suppression, and resistance that could be targeted for future treatments.

引用

页数：27

共 50 条

[1] Multiple myeloma: past, present and future
Andreeva, NE
[J]. GEMATOLOGIYA I TRANSFUZIOLOGIYA, 1998, 43 (03): : 4 - 11
[2] Glucocorticoids in multiple myeloma: past, present, and future
Nicholas Burwick
Sanjai Sharma
[J]. Annals of Hematology, 2019, 98 : 19 - 28
[3] Smoldering multiple myeloma - Past, present, and future
Mann, Hashim
Katiyar, Vatsala
Varga, Cindy
Comenzo, Raymond L.
[J]. BLOOD REVIEWS, 2022, 52
[4] Glucocorticoids in multiple myeloma: past, present, and future
Burwick, Nicholas
Sharma, Sanjai
[J]. ANNALS OF HEMATOLOGY, 2019, 98 (01) : 19 - 28
[5] Bisphosphonate therapy in multiple myeloma: past, present, future
Jantunen, E
[J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2002, 69 (5-6) : 257 - 264
[6] Bispecific antibodies for multiple myeloma: past, present and future
Ochi, Toshiki
Konishi, Tatsuya
Takenaka, Katsuto
[J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 120 (01) : 23 - 33
[7] Oncolytic Virotherapy for Multiple Myeloma: Past, Present, and Future
Thirukkumaran, Chandini M.
Morris, Don G.
[J]. BONE MARROW RESEARCH, 2011,
[8] Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma
Ackley, James
Ochoa, Miguel Armenta
Ghoshal, Delta
Roy, Krishnendu
Lonial, Sagar
Boise, Lawrence H.
[J]. CANCERS, 2021, 13 (19)
[9] Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future
Medina-Herrera, Alejandro
Sarasquete, Maria Eugenia
Jimenez, Cristina
Puig, Noemi
Garcia-Sanz, Ramon
[J]. CANCERS, 2023, 15 (14)
[10] Antimicrobial Irrigation Solutions in Root Canal Treatment: A Glance at the Past, the Present, and the Future
Qutieshat, Abubaker
Al Harthy, Nutayla
Al Busaidi, Shima
Al Sadoon, Ahmed
Al Sayahien, Dima
Sedqi, Maryam
Al Rashdi, Sumaiya
Al Ghammari, Samiya
[J]. OPEN DENTISTRY JOURNAL, 2023, 17

← 1 2 3 4 5 →